COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #206 of 237
12/9 Early treatment study
Agusti et al., Enfermedades Infecciosas y MicrobiologĂ­a ClĂ­nica, doi:10.1016/j.eimc.2020.10.023 (Peer Reviewed)
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial
Source   PDF   Share   Tweet
Small trial of low dose HCQ for healthcare workers with mild SARS-CoV-2 showing 68% lower progression to pneumonia, p = 0.21, and faster, but not statistically significant viral clearance.
There were no ICU admissions or deaths. Prospective non-randomized study. The figures and supplementary data are not currently available in the pre-proof edition.

Agusti et al., 12/9/2020, prospective, Spain, Europe, peer-reviewed, median age 37.0, 13 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
risk of disease progression, 68.4% lower, RR 0.32, p = 0.21, treatment 2 of 87 (2.3%), control 4 of 55 (7.3%), pneumonia.
time to viral-, 31.8% lower, relative time 0.68, treatment 87, control 55.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.